Cell division and the process to therapeutic vs reproductive cloning
... Placenta and Amniotic Membrane ...
... Placenta and Amniotic Membrane ...
save as PDF - BioCentury.com
... (BIRC5), such as sepantronium, and small molecule inhibitors of B cell CLL lymphoma 10 (BCL10) selectively induced apoptosis in undifferentiated cells. In a mixture of differentiated human cells and undifferentiated human stem cells injected into mice, none of the cell mixtures pretreated with sepan ...
... (BIRC5), such as sepantronium, and small molecule inhibitors of B cell CLL lymphoma 10 (BCL10) selectively induced apoptosis in undifferentiated cells. In a mixture of differentiated human cells and undifferentiated human stem cells injected into mice, none of the cell mixtures pretreated with sepan ...
HD Patient Stem Cells Advance Research
... protein in those cells would have begun to cause damage. Neonatal rats which had been injected with induced pluripotent stem cells from this line developed HD pathology at 33 weeks. As with humans, as the animals aged, their brains could no longer cope with the challenges presented by the mutant pro ...
... protein in those cells would have begun to cause damage. Neonatal rats which had been injected with induced pluripotent stem cells from this line developed HD pathology at 33 weeks. As with humans, as the animals aged, their brains could no longer cope with the challenges presented by the mutant pro ...
PD Dr. Tobias CANTZ
... Direct reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) is a promising approach for the derivation of disease-specific iPSCs. In the clinical setting, patient-specific iPSCs must undergo repair prior to autologous cell transplantation if the underlying condition was caused ...
... Direct reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) is a promising approach for the derivation of disease-specific iPSCs. In the clinical setting, patient-specific iPSCs must undergo repair prior to autologous cell transplantation if the underlying condition was caused ...
Quail Induced Pluripotent Stem Cells Derived
... levels of telomerase activity and clonal expansion after genetic manipulation qiPSC doubling time was 16.6 hr (n=3), significantly faster than the QEF cells (36.9 hr; P< 0.01) (A). Telomerase activity in qiPSC was higher than QEF (>11 fold, *P<0.01) and comparable to HeLa cells (P=0.07) (B). Eight d ...
... levels of telomerase activity and clonal expansion after genetic manipulation qiPSC doubling time was 16.6 hr (n=3), significantly faster than the QEF cells (36.9 hr; P< 0.01) (A). Telomerase activity in qiPSC was higher than QEF (>11 fold, *P<0.01) and comparable to HeLa cells (P=0.07) (B). Eight d ...
Plurioptent stem cell translation: basic and
... human embryonic stem cells in regenerative medicine Thirty years from the isolation of pluripotent mouse embryonic stem cells and over 13 years from the same accomplishment in humans, translational applications of this science are now underway. This includes the use of animal and human pluripotent s ...
... human embryonic stem cells in regenerative medicine Thirty years from the isolation of pluripotent mouse embryonic stem cells and over 13 years from the same accomplishment in humans, translational applications of this science are now underway. This includes the use of animal and human pluripotent s ...
STEM CELLS
... • A human body's master cell • STEM CELLS have two defining properties: 1) the ability to differentiate into other cells. 2) the ability to selfregenerate ...
... • A human body's master cell • STEM CELLS have two defining properties: 1) the ability to differentiate into other cells. 2) the ability to selfregenerate ...
DNMT3B controls fates in human pluripotent and nullipotent stem cells
... find that DNMT3B does not inhibit differentiation and apoptosis in pluripotent ES and EC cells. On the other hand, it facilitates differentiation of human ES cells, and acts as a barrier of induced pluripotency, suggesting its role in closed chromatin state. In contrast to the pluripotent stem cells ...
... find that DNMT3B does not inhibit differentiation and apoptosis in pluripotent ES and EC cells. On the other hand, it facilitates differentiation of human ES cells, and acts as a barrier of induced pluripotency, suggesting its role in closed chromatin state. In contrast to the pluripotent stem cells ...
P006 Could Stem Cells be a source for primary cells in HTS scenario?
... One of the main goals for the Pharmaceutical Industry is to reduce the high attrition rate in the final phases of the Drug Discovery process. The efficiency of this process will be highly improved if we can reveal the negative characteristic of the compounds in the early phases, as the HTS. This iss ...
... One of the main goals for the Pharmaceutical Industry is to reduce the high attrition rate in the final phases of the Drug Discovery process. The efficiency of this process will be highly improved if we can reveal the negative characteristic of the compounds in the early phases, as the HTS. This iss ...
2014-10-Chandrasekaran-Heidelberg-Abstract
... the pathology of certain diseases, especially when the affected tissue is hard to study, like in the CNS. Pluripotent cells, carrying the genotype of a given patient, can be differentiated in vitro to neural precursor cells (NPCs) which are then used to obtain neuronal and glial cells in culture. Th ...
... the pathology of certain diseases, especially when the affected tissue is hard to study, like in the CNS. Pluripotent cells, carrying the genotype of a given patient, can be differentiated in vitro to neural precursor cells (NPCs) which are then used to obtain neuronal and glial cells in culture. Th ...
1b. Induced pluripotent stem cells
... reprogrammed to an embryonic stem cell–like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. Although these cells meet the defining criteria for pluripotent stem cells, it is not known if iPSCs and embryonic stem cells diff ...
... reprogrammed to an embryonic stem cell–like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. Although these cells meet the defining criteria for pluripotent stem cells, it is not known if iPSCs and embryonic stem cells diff ...
Establishing a Territory Goal/Move 2
... Cell source is a major issue for tissue engineering and regenerative medicine. An exciting breakthrough in stem cell biology is that adult somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) by the activation of a limited number of genes1. The iPSCs derived from somatic cel ...
... Cell source is a major issue for tissue engineering and regenerative medicine. An exciting breakthrough in stem cell biology is that adult somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) by the activation of a limited number of genes1. The iPSCs derived from somatic cel ...
Prof. Dinko Mitrecic, MD, PhD Laboratory for Stem Cells
... Professor Elena N Kozlova,PhD Laboratory of Regenerative Neurobiology Uppsala University, Sweden ...
... Professor Elena N Kozlova,PhD Laboratory of Regenerative Neurobiology Uppsala University, Sweden ...
Induced pluripotent stem cell
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka’s lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon ""for the discovery that mature cells can be reprogrammed to become pluripotent."" Pluripotent stem cells hold great promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.The most well-known type of pluripotent stem cell is the embryonic stem cell. However, since the generation of embryonic stem cells involves destruction (or at least manipulation) of the pre-implantation stage embryo, there has been much controversy surrounding their use. Further, because embryonic stem cells can only be derived from embryos, it has so far not been feasible to create patient-matched embryonic stem cell lines.Since iPSCs can be derived directly from adult tissues, they not only bypass the need for embryos, but can be made in a patient-matched manner, which means that each individual could have their own pluripotent stem cell line. These unlimited supplies of autologous cells could be used to generate transplants without the risk of immune rejection. While the iPSC technology has not yet advanced to a stage where therapeutic transplants have been deemed safe, iPSCs are readily being used in personalized drug discovery efforts and understanding the patient-specific basis of disease.Depending on the methods used, reprogramming of adult cells to obtain iPSCs may pose significant risks that could limit their use in humans. For example, if viruses are used to genomically alter the cells, the expression of oncogenes (cancer-causing genes) may potentially be triggered. In February 2008, scientists announced the discovery of a technique that could remove oncogenes after the induction of pluripotency, thereby increasing the potential use of iPS cells in human diseases. In April 2009, it was demonstrated that generation of iPS cells is possible without any genetic alteration of the adult cell: a repeated treatment of the cells with certain proteins channeled into the cells via poly-arginine anchors was sufficient to induce pluripotency. The acronym given for those iPSCs is piPSCs (protein-induced pluripotent stem cells).